James Investment Research Inc. raised its position in Acorda Therapeutics Inc (NASDAQ:ACOR) by 42.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 40,290 shares of the biopharmaceutical company’s stock after purchasing an additional 12,000 shares during the period. James Investment Research Inc.’s holdings in Acorda Therapeutics were worth $535,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ACOR. Bank of Montreal Can raised its stake in shares of Acorda Therapeutics by 100.8% in the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,062 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Acorda Therapeutics in the 4th quarter valued at about $44,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Acorda Therapeutics in the 1st quarter valued at about $44,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Acorda Therapeutics in the 4th quarter valued at about $77,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Acorda Therapeutics by 869.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,241 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 9,185 shares during the period.
Shares of NASDAQ ACOR opened at $11.74 on Friday. The stock has a market capitalization of $564.69 million, a PE ratio of 9.95 and a beta of 1.34. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.77 and a quick ratio of 3.56. Acorda Therapeutics Inc has a fifty-two week low of $9.58 and a fifty-two week high of $36.35.
ACOR has been the topic of several recent research reports. Zacks Investment Research raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 8th. ValuEngine cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Acorda Therapeutics in a report on Monday, January 7th. BidaskClub cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 12th. Finally, HC Wainwright set a $33.00 price objective on Acorda Therapeutics and gave the company a “buy” rating in a report on Monday, January 14th. Four research analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. Acorda Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $22.56.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/05/acorda-therapeutics-inc-acor-shares-bought-by-james-investment-research-inc.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
See Also: What is the Dividend Aristocrat Index?
Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics Inc (NASDAQ:ACOR).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.